ArticleMedical oncology (Northwood, London, England)2025
Synthesis, characterization of ultrasmall gold nanocluster conjugated with Gemcitabine for anticancer activity.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective drug delivery strategy by employing novel nano-careers are advantageous for targeted and controlled drug release. The present work describes about such a strategy in the form of a protein stabilized ultrasmall gold nanocluster as nano-career for the delivery of anticancer drug Gemcitabine (Gem). Gold nanocluster (AuNCs) stabilized by bovine serum albumin (BSA) was synthesized and characterized in detail including its stability, size distribution, toxicity, and photo-physical properties. It was revealed that monodispersed gold particles (~ 1.5 nm) dispersible in aqueous phase with unique optical absorption and emission characteristics (λabs = 450 nm, λemi = 650 nm), high stability and minimum toxicity was obtained. Afterward, an anticancer drug (Gem) was conjugated with the gold cluster through simple chemical mixing resulting in the formation of 55% drug load Au nanocluster (Gem-AuNCs-BSA). The resultant Gem-AuNCs-BSA showed enhanced delivery of drug and therapeutic effects for the treatment of breast cancer and lung cancer with better efficacy than free Gemcitabine.
Indexed as
Identifiers
40514600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.